Prevalence of antibiotic resistance and integrons, sul and Smqnr genes in clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in Southwest Iran

Document Type: Original Article


1 Razi Clinical Research Development Center, Guilan University of Medical Sciences, Rasht, Iran

2 Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Microbiology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran

5 Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran


Objective(s): Stenotrophomonas maltophilia has emerged as an important opportunistic nosocomial pathogen due to its intrinsic and acquired resistance to a wide range of antimicrobial agents. The present study aimed to investigate the occurrence of antibiotic resistance and resistance mechanisms among clinical isolates of S. maltophilia from Iranian patients.
Materials and Methods: This cross-sectional study was performed on 44 S. maltophilia isolates that were recovered from different clinical specimens in 2015 and 2016. Conventional microbiologic methods were used for primary identification of isolates and confirmed by specific polymerase chain reaction (PCR) primers. Minimum inhibitory concentrations (MICs) were determined by the E-test. PCR was applied to determine antibiotic resistance genes.
Results: All of S. maltophilia isolates were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX) and colistin. Moreover, the susceptibility rates of isolates toward ceftazidime and ciprofloxacin were 93.2%, and 84.1%, respectively. Class 1 integrons was detected in 24 (54.5%) isolates by the presence of int1 gene. Moreover, the prevalence of antibiotic resistance genes sul1, sul2, and Smqnr were found in 16 (36.4%), 15 (34.1%), and 29 (65.9%) isolates, respectively.
Conclusion: In summary, the prevalence of sul and Smqnr genes in integrons-contained isolates point out the significant risk of sulfonamides and fluoroquinolones resistance among clinical isolates of S. maltophilia in our region.


Main Subjects

1.  Adegoke AA, Stenstrom TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol 2017; 8:2276.
2. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007; 109:2615-2622.
3. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6:893-912.
4. Jia W, Wang J, Xu H, Li G. Resistance of Stenotrophomonas maltophilia to fluoroquinolones: prevalence in a University Hospital and possible mechanisms. Int J Environ Res Public Health 2015; 12:5177-5195.
5. Motamedifar M, Heidari H, Yasemi M, Sedigh Ebrahim-Saraie H. Molecular epidemiology and characteristics of 16 cases with Stenotrophomonas maltophilia bacteraemia in pediatric Intensive Care Units. Ann Ig 2017; 29:264-272.
6. Neela V, Rankouhi SZ, van Belkum A, Goering RV, Awang R. Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance. Int J Infect Dis 2012; 16:e603-607.
7. Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006; 5:23-25.
8. Sanchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol 2015; 6:658-704.
9. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 2007; 13:559-565.
10. Soltani B, Heidari H, Ebrahim-Saraie HS, Hadi N, Mardaneh J, Motamedifar M. Molecular characteristics of multiple and extensive drug-resistant Acinetobacter baumannii isolates obtained from hospitalized patients in Southwestern Iran. Infez Med 2018; 26:67-76.
11. Ba BB, Feghali H, Arpin C, Saux MC, Quentin C. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:946-953.
12. Gordon NC, Wareham DW. Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2010; 65:483-489.
13. Malekan M, Tabaraie B, Akhoundtabar L, Afrough P, Behrouzi A. Distribution of class I integron and smqnr resistance gene among Stenotrophomonas maltophilia isolated from clinical samples in Iran. Avicenna J Med Biotechnol 2017; 9:138-141.
14. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 2010; 362:1804-1813.
15. Gallo SW, Ramos PL, Ferreira CA, Oliveira SD. A specific polymerase chain reaction method to identify Stenotrophomonas maltophilia. Mem Inst Oswaldo Cruz 2013; 108:390–391.
16. Wayne PA. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute (CLSI) 2017; 27th Informational Supplement.
17. Heidari H, Emaneini M, Dabiri H, Jabalameli F. Virulence factors, antimicrobial resistance pattern and molecular analysis of Enterococcal strains isolated from burn patients. Microb Pathog 2016; 90:93-97.
18. Byrne-Bailey KG, Gaze WH, Kay P, Boxall AB, Hawkey PM, Wellington EM. Prevalence of sulfonamide resistance genes in bacterial isolates from manured agricultural soils and pig slurry in the United Kingdom. Antimicrob Agents Chemother 2009; 53:696-702.
19. Machado E, Canton R, Baquero F, Galan JC, Rollan A, Peixe L, et al. Integron content of extended-spectrum-beta-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Antimicrob Agents Chemother 2005; 49:1823-1829.
20. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2-41.
21. Ghaffarian F, Hedayati M, Sedigh Ebrahim-Saraie H, Atrkar Roushan Z, Mojtahedi A. Molecular epidemiology of ESBL-producing Klebsiella pneumoniae isolates in intensive care units of a tertiary care hospital, North of Iran. Cell Mol Biol (Noisy-le-grand) 2018; 64:75-79.
22. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602-1609.
23. Nemati AH, Solgi H, Vaziri F, Shahcheraghi F. Antimicrobial susceptibility of Stenotrophomonas maltophilia clinical isolates from blood samples in Iran. J Med Microbiol Infect Dis 2015; 3:35-37.
24. Jamali F, Boroumand MA, Yazdani F, Anvari MS, Pourgholi L, Mahfouzi S, et al. Minimal inhibitory concentration of ceftazidime and co-trimoxazole for Stenotrophomonas Maltophilia using E-test. J Glob Infect Dis 2011; 3:254-258.
25. Paopradit P, Srinitiwarawong K, Ingviya N, Singkhamanan K, Vuddhakul V. Distribution and characterization of Stenotrophomonas maltophilia isolates from environmental and clinical samples in Thailand. J Hosp Infect 2017; 97:185-191.
26. Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al. Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 2011; 37:230-234.
27. Kanamori H, Yano H, Tanouchi A, Kakuta R, Endo S, Ichimura S, et al. Prevalence of Smqnr and plasmid-mediated quinolone resistance determinants in clinical isolates of Stenotrophomonas maltophilia from Japan: novel variants of Smqnr. New Microbes New Infect 2015; 7:8-14.
28. Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012; 45:120-126.
29. Chung HS, Kim K, Hong SS, Hong SG, Lee K, Chong Y. The sul1 gene in Stenotrophomonas maltophilia with high-level resistance to trimethoprim/sulfamethoxazole. Ann Lab Med 2015; 35:246-249.
30. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54:2735-2737.
31. Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasilis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 2012; 7:e37375.
32. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis 2013; 76:217-221.
33. Rodriguez CH, Nastro M, Calvo JL, Farina ME, Dabos L, Famiglietti A. In vitro activity of colistin against Stenotrophomonas maltophilia. J Glob Antimicrob Resist 2014; 2:316-317.
34. Domingues S, da Silva GJ, Nielsen KM. Integrons: Vehicles and pathways for horizontal dissemination in bacteria. Mob Genet Elements 2012; 2:211-223.
35. Kaur P, Gautam V, Tewari R. Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care Hospital in North India. Microb Drug Resist 2015; 21:380-385.
36. Usta E, Eroʇlu C, Yanik K, Karadaʇ A, Güney AK, Günaydin M. Investigation of the presence of class 1, 2, 3 integrons and their relationships with antibiotic resistance in clinical stenotrophomonas maltophilia isolates. Mikrobiyoloji Bulteni 2015; 49:35-46.
37. Morsi SS, Sharaf HE, Gerges MA. Association of sul genes and class 1 integron with trimethoprim-sulfamethoxazole Resistance in Stenotrophomonas maltophilia clinical isolates in Zagazig University, Egypt. Afr J Clin Exp Microbiol 2016; 17:158-165.
38. Tanimoto K. Stenotrophomonas maltophilia strains isolated from a university hospital in Japan: genomic variability and antibiotic resistance. J Med Microbiol 2013; 62:565-570.
39. Hu LF, Chen GS, Kong QX, Gao LP, Chen X, Ye Y, et al. Increase in the prevalence of resistance determinants to trimethoprim/sulfamethoxazole in clinical Stenotrophomonas maltophilia isolates in China. PLoS One 2016; 11:e0157693.
40. Zhang R, Sun Q, Hu YJ, Yu H, Li Y, Shen Q, et al. Detection of the Smqnr quinolone protection gene and its prevalence in clinical isolates of Stenotrophomonas maltophilia in China. J Med Microbiol 2012; 61:535-539.